-
Japan discards 2.5m doses of expired COVID drugs from Pfizer, Merck
15 Jul 2025 20:16 GMT
… 1.75 million doses of Pfizer's Paxlovid were discarded …
-
Pfizer describes new STAT6 inhibitors
15 Jul 2025 20:14 GMT
Neurology/psychiatric
Pfizer Inc. has identified signal transducer …
-
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
11 Jul 2025 13:08 GMT
… different times by companies, including Pfizer Inc. PFE, Boehringer Ingelheim, Sanofi … to proceed.
In May 2024, Pfizer settled 10,000 lawsuits alleging …
-
Pfizer and Astellas’ Xtandi improves OS as combination therapy
11 Jul 2025 10:27 GMT
Pfizer and Astellas’ Xtandi (enzalutamide) has … versus placebo plus leuprolide.
Although Pfizer and Astellas have not yet …
-
HIGHLY CORRUPT PFIZER wonât release MYOCARDITIS study results because vaccine âsafetyâ claim will obviously get blown out of the water
11 Jul 2025 09:44 GMT
… or pericarditis after receiving Pfizer’s vaccine, with a … study’s credibility.
Despite Pfizer’s delay, independent studies … required stronger warning labels for Pfizer and Moderna vaccines. Current … websites for updates on Pfizer’s experimental gene therapy …
-
Functional Dyspepsia Market Analysis And Forecast, 2025-2035, Competitive Analysis Of Astrazeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong
11 Jul 2025 09:39 GMT
… . Major players include AstraZeneca and Pfizer, highlighting a competitive landscape ripe … . Reddy's Laboratories Ltd Pfizer ZERIA Pharmaceutical Co., Ltd. Daewoong …
-
Sally Susman waves goodbye to Pfizer; Xaira's new president and COO
11 Jul 2025 11:21 GMT
-
Burns Market Analysis And Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, Deroyal Industries
11 Jul 2025 09:39 GMT
(MENAFN- GlobeNewsWire - Nasdaq) The global burns market is experiencing significant growth, fueled by rising burn incidences and enhanced awareness of wound care. Increased occurrences of road accidents and industrial mishaps have propelled the demand for …
-
Pfizer & Astellas Pharma announces positive results from phase 3 EMBARK study of Xtandi plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with BCR
11 Jul 2025 04:33 GMT
… ., oncology chief development officer, Pfizer. “These positive results add … trial exemplify Astellas’ and Pfizer’s longstanding commitment to the … which is now part of Pfizer, and Astellas entered into … on Biology and Modality.
Pfizer Oncology is the forefront …
-
Pfizer, Astellas boost case for Xtandi in early-stage prostate cancer with combo survival win
11 Jul 2025 00:14 GMT
Pfizer and Astellas are underlining the … meaningful improvement” in overall survival, Pfizer announced in a July 10 … when they start Xtandi early,” Pfizer's oncology chief development …
About
© 1995-2025